BioCentury
ARTICLE | Clinical News

Momenta gains on Phase I data for anti-FCRN mAb

January 5, 2018 11:59 PM UTC

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) added $2.80 (19%) to $17.55 on Friday after reporting that its immune-mediated disease candidate M281 was safe and showed proof of mechanism in a Phase I trial in healthy volunteers. M281 is a human IgG1 mAb against neonatal Fc receptor (FCRN; FCGRT).

Momenta said multiple ascending doses of M281 reduced circulating levels of IgG antibodies by up to 89% over the 98-day study, while single ascending doses of M281 reduced the measure by up to 80%. M281 was well tolerated with no serious adverse events reported. The double-blind, placebo-controlled trial enrolled 50 healthy volunteers...